Enrico Santinelli
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Enrico Santinelli has a total of 30 co-authors. Here are the top co-authors by number of shared publications:
- Carmelo Gurnari
Department of Translational Hematology and Oncology Research Taussig Cancer Institute, Cleveland Clinic Cleveland Ohio USA
2 shared publications - Emiliano Fabiani
Department of Biomedicine and Prevention, University of Rome Tor Vergata, Rome, Italy
2 shared publications - Maria Teresa Voso
Department of Biomedicine and Prevention University of Rome Tor Vergata Rome Italy
2 shared publications - Alessandra Marinucci
Operative Research Unit of Transfusion Medicine and Cellular Therapy, Fondazione Policlinico Universitario Campus Bio-Medico, 00128 Roma, Italy
1 shared publication - Antonio Cristiano
Operative Research Unit of Laboratory, Fondazione Policlinico Universitario Campus Bio-Medico, Rome, Italy.
1 shared publication - Carolina Nobile
Operative Research Unit of Transfusion Medicine and Cellular Therapy, Fondazione Policlinico Universitario Campus Bio-Medico, 00128 Roma, Italy
1 shared publication
Latest Publications
- Open Access
- 22 April 2025
- Published by Elsevier in Leukemia Research
- Vol. 153, 107703
The role of morphology in diagnosing MDS with Non-clonal cytopenias
- 22 April 2025
- Published by Elsevier in Leukemia Research
- Vol. 153, 107703
Open AccessThe role of morphology in diagnosing MDS with Non-clonal cytopenias
- Open Access
Stem Cells Collection and Mobilization in Adult Autologous/Allogeneic Transplantation: Critical Points and Future Challenges
Achieving successful hematopoietic stem cell transplantation (HSCT) relies on two fundamental pillars: effective mobilization and efficient collection through apheresis to attain the optimal graft dose. These cornerstones pave the way for enhanced patient outcomes. The primary challenges encountered by the clinical unit and collection facility within a transplant program encompass augmenting mobilization efficiency to optimize the harvest of target cell populations, implementing robust monitoring and predictive strategies for mobilization, streamlining the apheresis procedure to minimize collection duration while ensuring adequate yield, prioritizing patient comfort by reducing the overall collection time, guaranteeing the quality and purity of stem cell products to optimize graft function and transplant success, and facilitating seamless coordination between diverse entities involved in the HSCT process. In this review, we aim to address key questions and provide insights into the critical aspects of mobilizing and collecting hematopoietic stem cells for transplantation purposes.
Open AccessStem Cells Collection and Mobilization in Adult Autologous/Allogeneic Transplantation: Critical Points and Future Challenges
Achieving successful hematopoietic stem cell transplantation (HSCT) relies on two fundamental pillars: effective mobilization and efficient collection through apheresis to attain the optimal graft dose. These cornerstones pave the way for enhanced patient outcomes. The primary challenges encountered by the clinical unit and collection facility within a transplant program encompass augmenting mobilization efficiency to optimize the harvest of target cell populations, implementing robust monitoring and predictive strategies for mobilization, streamlining the apheresis procedure to minimize collection duration while ensuring adequate yield, prioritizing patient comfort by reducing the overall collection time, guaranteeing the quality and purity of stem cell products to optimize graft function and transplant success, and facilitating seamless coordination between diverse entities involved in the HSCT process. In this review, we aim to address key questions and provide insights into the critical aspects of mobilizing and collecting hematopoietic stem cells for transplantation purposes.
- 30 January 2024
- Published by Springer Nature in Bone Marrow Transplantation
- Vol. 59 (4) , 444-450
Diagnostic evaluation in bone marrow failure disorders: what have we learnt to help inform the transplant decision in 2024 and beyond?
Aplastic anemia (AA) is the prototypical bone marrow failure syndrome. In the current era of readily available ‘molecular annotation’, application of comprehensive next-generation sequencing panels has generated novel insights into underlying pathogenetic mechanisms, potentially leading to improvements in personalized therapeutic approaches. New evidence has emerged as to the role of somatic loss of HLA class I allele expression in ‘immune-mediated’ AA, associated molecular aberrations, and risk of clonal evolution. A deeper understanding has emerged regarding the role of ‘myeloid’ gene mutations in this context, translating patho-mechanistic insights derived from wider clinical and translational research within the myeloid disorder arena. Here, we review contemporary ‘tools’ which aid in confirmation of a diagnosis of AA, with an additional focus on their potential in guiding therapeutic options. A specific emphasis is placed upon interpretation and integration of this detailed diagnostic information and how this may inform optimal transplantation strategies.
- 30 January 2024
- Published by Springer Nature in Bone Marrow Transplantation
- Vol. 59 (4) , 444-450
Diagnostic evaluation in bone marrow failure disorders: what have we learnt to help inform the transplant decision in 2024 and beyond?
Aplastic anemia (AA) is the prototypical bone marrow failure syndrome. In the current era of readily available ‘molecular annotation’, application of comprehensive next-generation sequencing panels has generated novel insights into underlying pathogenetic mechanisms, potentially leading to improvements in personalized therapeutic approaches. New evidence has emerged as to the role of somatic loss of HLA class I allele expression in ‘immune-mediated’ AA, associated molecular aberrations, and risk of clonal evolution. A deeper understanding has emerged regarding the role of ‘myeloid’ gene mutations in this context, translating patho-mechanistic insights derived from wider clinical and translational research within the myeloid disorder arena. Here, we review contemporary ‘tools’ which aid in confirmation of a diagnosis of AA, with an additional focus on their potential in guiding therapeutic options. A specific emphasis is placed upon interpretation and integration of this detailed diagnostic information and how this may inform optimal transplantation strategies.
- 22 September 2023
- Published by Elsevier in Experimental Hematology
- Vol. 129, 104118-104129
Microenvironment in acute myeloid leukemia: focus on senescence mechanisms, therapeutic interactions, and future directions
- 22 September 2023
- Published by Elsevier in Experimental Hematology
- Vol. 129, 104118-104129
Microenvironment in acute myeloid leukemia: focus on senescence mechanisms, therapeutic interactions, and future directions